Hemostemix Inc. (HMTXF)
USD 0.07
(2.96%)
USD 0.07
(2.96%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 313.76 Thousand CAD | -32.57% |
| 2022 | 465.34 Thousand CAD | -17.35% |
| 2021 | 563.04 Thousand CAD | -75.76% |
| 2020 | 2.32 Million CAD | 2127.73% |
| 2019 | 104.28 Thousand CAD | -93.73% |
| 2018 | 1.66 Million CAD | -68.65% |
| 2017 | 5.3 Million CAD | 2234.76% |
| 2016 | 227.11 Thousand CAD | -71.5% |
| 2015 | 796.8 Thousand CAD | -79.78% |
| 2014 | 3.94 Million CAD | 382.51% |
| 2013 | 816.84 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 243.77 Thousand CAD | 158.35% |
| 2024 Q1 | 94.36 Thousand CAD | -69.93% |
| 2023 FY | 313.76 Thousand CAD | -32.57% |
| 2023 Q1 | 500.7 Thousand CAD | 7.6% |
| 2023 Q4 | 313.76 Thousand CAD | -55.25% |
| 2023 Q3 | 701.14 Thousand CAD | 129.8% |
| 2023 Q2 | 305.11 Thousand CAD | -39.06% |
| 2022 Q3 | 1.17 Million CAD | 42.42% |
| 2022 FY | 465.34 Thousand CAD | -17.35% |
| 2022 Q1 | 1.34 Million CAD | 139.73% |
| 2022 Q2 | 821.99 Thousand CAD | -39.1% |
| 2022 Q4 | 465.34 Thousand CAD | -60.25% |
| 2021 Q1 | 925.96 Thousand CAD | -60.14% |
| 2021 FY | 563.04 Thousand CAD | -75.76% |
| 2021 Q2 | 2.91 Million CAD | 214.64% |
| 2021 Q4 | 563.04 Thousand CAD | -76.42% |
| 2021 Q3 | 2.38 Million CAD | -18.02% |
| 2020 Q1 | 483.93 Thousand CAD | 364.07% |
| 2020 Q2 | 609.8 Thousand CAD | 26.01% |
| 2020 Q3 | 253.41 Thousand CAD | -58.44% |
| 2020 Q4 | 2.32 Million CAD | 816.72% |
| 2020 FY | 2.32 Million CAD | 2127.73% |
| 2019 Q3 | 284.05 Thousand CAD | 177.63% |
| 2019 Q2 | 102.31 Thousand CAD | -85.39% |
| 2019 FY | 104.28 Thousand CAD | -93.73% |
| 2019 Q1 | 700.12 Thousand CAD | -57.88% |
| 2019 Q4 | 104.28 Thousand CAD | -63.29% |
| 2018 Q2 | 3.94 Million CAD | -21.22% |
| 2018 FY | 1.66 Million CAD | -68.65% |
| 2018 Q1 | 5 Million CAD | -5.55% |
| 2018 Q3 | 2.74 Million CAD | -30.42% |
| 2018 Q4 | 1.66 Million CAD | -39.45% |
| 2017 Q4 | 5.3 Million CAD | -9.89% |
| 2017 Q2 | 251.32 Thousand CAD | -35.97% |
| 2017 Q3 | 5.88 Million CAD | 2241.39% |
| 2017 Q1 | 392.51 Thousand CAD | 72.83% |
| 2017 FY | 5.3 Million CAD | 2234.76% |
| 2016 Q3 | 393.48 Thousand CAD | 19.17% |
| 2016 FY | 227.11 Thousand CAD | -71.5% |
| 2016 Q4 | 227.11 Thousand CAD | -42.28% |
| 2016 Q2 | 330.18 Thousand CAD | -5.44% |
| 2016 Q1 | 349.19 Thousand CAD | -56.18% |
| 2015 Q3 | 1.2 Million CAD | -45.8% |
| 2015 Q1 | 3.06 Million CAD | -22.2% |
| 2015 Q2 | 2.22 Million CAD | -27.34% |
| 2015 FY | 796.8 Thousand CAD | -79.78% |
| 2015 Q4 | 796.8 Thousand CAD | -34.01% |
| 2014 Q3 | 174.29 Thousand CAD | -27.67% |
| 2014 FY | 3.94 Million CAD | 382.51% |
| 2014 Q1 | 215.98 Thousand CAD | -8.75% |
| 2014 Q4 | 3.94 Million CAD | 2161.34% |
| 2014 Q2 | 240.97 Thousand CAD | 11.57% |
| 2013 Q4 | 236.68 Thousand CAD | -6.88% |
| 2013 Q3 | 254.16 Thousand CAD | -8.36% |
| 2013 Q1 | 295.63 Thousand CAD | 142.25% |
| 2013 FY | 816.84 Thousand CAD | 0.0% |
| 2013 Q2 | 277.34 Thousand CAD | -6.19% |
| 2012 Q3 | 126 Thousand CAD | 0.0% |
| 2012 Q4 | 122.03 Thousand CAD | -3.14% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.405% |
| Skye Bioscience, Inc. | 11.94 Million USD | 97.372% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.759% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 43.171% |
| Qrons Inc. | 420.00 USD | -74605.952% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 34.708% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 83.977% |
| BioStem Technologies, Inc. | 14.56 Million USD | 97.845% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 11.27% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 98.877% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 97.027% |
| Rebus Holdings, Inc. | 5000.00 USD | -6175.3% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -13482.9% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 59.285% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 54.361% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.192% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 95.654% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -310.935% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.707% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 78.09% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -333.587% |
| Mesoblast Limited | 667.9 Million USD | 99.953% |
| Marizyme, Inc. | 22.01 Million USD | 98.575% |
| Genus plc | 1.02 Billion USD | 99.97% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 76.901% |
| Pharming Group N.V. | 462.85 Million USD | 99.932% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 90.529% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 37.126% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 49.958% |
| ContraFect Corporation | 20.67 Million USD | 98.483% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 19.623% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 17.901% |
| IMV Inc. | 31.33 Million USD | 98.999% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 92.432% |
| MultiCell Technologies, Inc. | 126.22 USD | -248485.803% |
| ONE Bio Corp. | 70.08 Million USD | 99.552% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 66.61% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.756% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 27.321% |
| Q BioMed Inc. | 3.51 Million USD | 91.075% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.108% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -20.089% |
| Biomind Labs Inc. | 73.81 Thousand USD | -325.046% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.93% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 78.344% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 98.955% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 88.575% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 87.947% |
| GB Sciences, Inc. | 103.44 Thousand USD | -203.325% |
| Alpha Cognition Inc. | 2.45 Million USD | 87.205% |
| HST Global, Inc. | 1526.00 USD | -20461.271% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 68.241% |
| Halberd Corporation | 10.13 Thousand USD | -2997.078% |
| Enzolytics Inc. | 361.7 Million USD | 99.913% |
| Agentix Corp. | 261.39 Thousand USD | -20.036% |
| Resverlogix Corp. | 8.11 Million USD | 96.134% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 83.292% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.993% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.342% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 50.948% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -1277.31% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 96.494% |
| AVAX Technologies, Inc. | 7.37 Million USD | 95.747% |
| Zenith Capital Corp. | 7410.00 USD | -4134.345% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.991% |
| Ember Therapeutics, Inc. | 184.00 USD | -170424.457% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 2.499% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -20.049% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 66.188% |
| Kadimastem Ltd | 2.3 Million USD | 86.382% |
| Helix BioMedix, Inc. | 3.02 Million USD | 89.628% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -449.559% |
| LadRx Corporation | 2.3 Million USD | 86.405% |
| Cell Source, Inc. | 195.17 Thousand USD | -60.764% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 11.27% |
| NovAccess Global Inc. | 62.24 Thousand USD | -404.056% |
| Affymax, Inc. | 7.44 Million USD | 95.784% |
| Itoco Inc. | 1.4 Million USD | 77.589% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -228.01% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -196.005% |
| Mobile Lads Corp. | 52.00 USD | -603294.231% |
| CytoDyn Inc. | 11.13 Million USD | 97.182% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -119.459% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -1654.838% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 18.602% |
| SYBLEU INC | 330.46 Thousand USD | 5.054% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 23.364% |
| International Stem Cell Corporation | 5.39 Million USD | 94.179% |
| Bioxytran, Inc. | 137.63 Thousand USD | -127.964% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 97.908% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 98.107% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -297.171% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 63.713% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 95.826% |
| Neutra Corp. | 2851.00 USD | -10905.437% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.032% |
| PureTech Health plc | 693.97 Million USD | 99.955% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 96.112% |
| IXICO plc | 15.84 Million USD | 98.02% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 96.211% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.696% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Cellectis S.A. | 333.99 Million USD | 99.906% |